Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Therapeutic Use
- Acronyms CHICO
- Sponsors Bayer
- 10 Jul 2017 Planned End Date changed from 30 Nov 2018 to 31 Jul 2018.
- 10 Jul 2017 Planned primary completion date changed from 30 Nov 2018 to 31 Jul 2018.
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.